Financial Ratios Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Equities
600276
CNE0000014W7
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.99 CNY | -0.76% |
|
-4.76% | -0.97% |
| Jan. 22 | Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs | MT |
| Jan. 20 | Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 12.59 | 6.38 | 4.62 | 6.06 | 8.62 | |||||
Return on Total Capital | 14.07 | 7.1 | 4.99 | 6.45 | 9.27 | |||||
Return On Equity % | 22.64 | 13.51 | 10.31 | 10.77 | 14.55 | |||||
Return on Common Equity | 22.9 | 13.83 | 10.73 | 10.99 | 14.74 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 87.9 | 85.5 | 83.53 | 84.39 | 86.13 | |||||
SG&A Margin | 46.4 | 47.26 | 45.38 | 43.8 | 38.92 | |||||
EBITDA Margin % | 24.23 | 16.49 | 16.66 | 21.17 | 25.71 | |||||
EBITA Margin % | 22.65 | 14.62 | 14.23 | 18.41 | 23.37 | |||||
EBIT Margin % | 22.61 | 14.58 | 14.17 | 18.3 | 23.14 | |||||
Income From Continuing Operations Margin % | 22.75 | 17.31 | 17.93 | 18.75 | 22.64 | |||||
Net Income Margin % | 22.82 | 17.49 | 18.36 | 18.85 | 22.64 | |||||
Net Avail. For Common Margin % | 22.82 | 17.49 | 18.36 | 18.85 | 22.64 | |||||
Normalized Net Income Margin | 15.39 | 10.62 | 11.81 | 12.86 | 15.75 | |||||
Levered Free Cash Flow Margin | 9.39 | 4.99 | -9.66 | 21.38 | 15.76 | |||||
Unlevered Free Cash Flow Margin | 9.39 | 5 | -9.64 | 21.4 | 15.77 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.89 | 0.7 | 0.52 | 0.53 | 0.6 | |||||
Fixed Assets Turnover | 6.41 | 4.77 | 3.29 | 3.43 | 4.13 | |||||
Receivables Turnover (Average Receivables) | 4.06 | 3.42 | 2.79 | 3.09 | 4.07 | |||||
Inventory Turnover (Average Inventory) | 1.98 | 1.8 | 1.44 | 1.5 | 1.64 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.44 | 8.87 | 8.5 | 12.25 | 9.72 | |||||
Quick Ratio | 6.7 | 7.72 | 7.36 | 10.74 | 8.62 | |||||
Operating Cash Flow to Current Liabilities | 0.91 | 1.24 | 0.35 | 2.99 | 2.04 | |||||
Days Sales Outstanding (Average Receivables) | 90.2 | 106.61 | 130.99 | 118.06 | 89.96 | |||||
Days Outstanding Inventory (Average Inventory) | 184.58 | 203.16 | 252.82 | 244.08 | 223.1 | |||||
Average Days Payable Outstanding | 141.22 | 127.97 | 175.43 | 150.62 | 130.98 | |||||
Cash Conversion Cycle (Average Days) | 133.56 | 181.8 | 208.38 | 211.53 | 182.08 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | - | 0.43 | 3.54 | 0.18 | 0.24 | |||||
Total Debt / Total Capital | - | 0.42 | 3.42 | 0.18 | 0.24 | |||||
LT Debt/Equity | - | 0.43 | 0.26 | 0.18 | 0.15 | |||||
Long-Term Debt / Total Capital | - | 0.42 | 0.25 | 0.18 | 0.15 | |||||
Total Liabilities / Total Assets | 11.35 | 9.41 | 9.31 | 6.28 | 8.07 | |||||
EBIT / Interest Expense | - | 801.73 | 464.37 | 707.35 | 1.16K | |||||
EBITDA / Interest Expense | - | 911.93 | 552.06 | 824.66 | 1.3K | |||||
(EBITDA - Capex) / Interest Expense | - | 558.52 | 245.19 | 573.33 | 949.62 | |||||
Total Debt / EBITDA | - | 0.04 | 0.38 | 0.02 | 0.02 | |||||
Net Debt / EBITDA | -2.45 | -4.32 | -4.61 | -4.27 | -3.45 | |||||
Total Debt / (EBITDA - Capex) | - | 0.06 | 0.85 | 0.02 | 0.02 | |||||
Net Debt / (EBITDA - Capex) | -2.67 | -7.06 | -10.37 | -6.14 | -4.73 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 19.09 | -6.6 | -17.87 | 7.26 | 22.63 | |||||
Gross Profit, 1 Yr. Growth % | 19.68 | -9.14 | -19.76 | 8.36 | 25.17 | |||||
EBITDA, 1 Yr. Growth % | 9.81 | -36.45 | -16.79 | 34.22 | 48.56 | |||||
EBITA, 1 Yr. Growth % | 14.01 | -39.71 | -19.8 | 36.33 | 55.17 | |||||
EBIT, 1 Yr. Growth % | 14 | -39.79 | -19.92 | 36.49 | 55.07 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 18.44 | -28.93 | -14.92 | 12.13 | 48.14 | |||||
Net Income, 1 Yr. Growth % | 18.78 | -28.41 | -13.77 | 10.14 | 47.28 | |||||
Normalized Net Income, 1 Yr. Growth % | 16.55 | -35.54 | -4.17 | 15.54 | 50.2 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 19.01 | -28.28 | -14.08 | 11.48 | 47.06 | |||||
Accounts Receivable, 1 Yr. Growth % | 50.43 | -15.8 | 21.17 | -26.45 | 0.4 | |||||
Inventory, 1 Yr. Growth % | 10.66 | 35.13 | 1.99 | -5.57 | 4.46 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 12.53 | 36.87 | 6.38 | -0.69 | 4.51 | |||||
Total Assets, 1 Yr. Growth % | 26.03 | 13.06 | 7.87 | 3.34 | 14.51 | |||||
Tangible Book Value, 1 Yr. Growth % | 23.49 | 14.58 | 7.94 | 6.11 | 11.99 | |||||
Common Equity, 1 Yr. Growth % | 23.12 | 14.75 | 8.06 | 6.99 | 12.49 | |||||
Cash From Operations, 1 Yr. Growth % | -10.08 | 22.93 | -70.01 | 504.12 | -2.89 | |||||
Capital Expenditures, 1 Yr. Growth % | -1.25 | 200.3 | 19.68 | -25.52 | 32.71 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -71.45 | -49.99 | -278.65 | -340.33 | -9.36 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -71.45 | -49.88 | -277.84 | -341 | -9.36 | |||||
Dividend Per Share, 1 Yr. Growth % | 4.32 | -4.02 | 0 | 25 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 26.19 | 5.47 | -12.42 | -6.14 | 14.69 | |||||
Gross Profit, 2 Yr. CAGR % | 27.15 | 4.28 | -14.62 | -6.76 | 16.46 | |||||
EBITDA, 2 Yr. CAGR % | 23.04 | -16.46 | -27.37 | 6.48 | 41.39 | |||||
EBITA, 2 Yr. CAGR % | 24.28 | -17.1 | -30.56 | 5.49 | 45.66 | |||||
EBIT, 2 Yr. CAGR % | 24.29 | -17.15 | -30.67 | 5.32 | 45.48 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 24.64 | -8.25 | -22.24 | -2.33 | 28.88 | |||||
Net Income, 2 Yr. CAGR % | 24.76 | -7.79 | -21.43 | -2.55 | 27.36 | |||||
Normalized Net Income, 2 Yr. CAGR % | 24.04 | -13.32 | -23.29 | 5.82 | 31.74 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 24.59 | -7.69 | -21.5 | -2.14 | 28.04 | |||||
Accounts Receivable, 2 Yr. CAGR % | 35.83 | 12.54 | 1.01 | -5.6 | -14.07 | |||||
Inventory, 2 Yr. CAGR % | 31.35 | 22.28 | 17.4 | -1.86 | -0.68 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 11.53 | 24.1 | 20.66 | 2.78 | 1.87 | |||||
Total Assets, 2 Yr. CAGR % | 24.62 | 19.37 | 10.43 | 5.6 | 8.78 | |||||
Tangible Book Value, 2 Yr. CAGR % | 24.51 | 18.95 | 11.21 | 7.02 | 9.01 | |||||
Common Equity, 2 Yr. CAGR % | 24.35 | 18.86 | 11.35 | 7.52 | 9.7 | |||||
Cash From Operations, 2 Yr. CAGR % | 11.22 | 5.13 | -39.28 | 34.6 | 142.21 | |||||
Capital Expenditures, 2 Yr. CAGR % | 2.36 | 72.2 | 89.57 | -5.59 | -0.58 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -30.57 | -62.36 | -10.8 | 105.93 | 47.39 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -30.57 | -62.32 | -10.89 | 105.74 | 47.59 | |||||
Dividend Per Share, 2 Yr. CAGR % | 14.43 | 0.06 | -2.03 | 11.8 | 11.8 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 26.09 | 14.15 | -2.97 | -6.29 | 2.61 | |||||
Gross Profit, 3 Yr. CAGR % | 26.71 | 13.67 | -4.45 | -7.56 | 2.86 | |||||
EBITDA, 3 Yr. CAGR % | 19.96 | -1.28 | -16.64 | -10.42 | 19.08 | |||||
EBITA, 3 Yr. CAGR % | 20.59 | -2.35 | -18.08 | -12.54 | 20.09 | |||||
EBIT, 3 Yr. CAGR % | 20.6 | -2.38 | -18.17 | -12.68 | 19.82 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 24.2 | 3.36 | -10.53 | -12.15 | 12.22 | |||||
Net Income, 3 Yr. CAGR % | 25.3 | 3.67 | -9.83 | -12.07 | 11.83 | |||||
Normalized Net Income, 3 Yr. CAGR % | 24.62 | -0.28 | -11.81 | -11.74 | 18.92 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 25.35 | 3.58 | -9.88 | -11.77 | 12.09 | |||||
Accounts Receivable, 3 Yr. CAGR % | 25.09 | 15.81 | 15.35 | -9.13 | -3.64 | |||||
Inventory, 3 Yr. CAGR % | 31.07 | 32.6 | 15.11 | 9.18 | 0.2 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 14.2 | 19.41 | 17.89 | 13.08 | 3.35 | |||||
Total Assets, 3 Yr. CAGR % | 24.4 | 20.64 | 15.41 | 8.03 | 8.49 | |||||
Tangible Book Value, 3 Yr. CAGR % | 25.97 | 21.11 | 15.16 | 9.48 | 8.65 | |||||
Common Equity, 3 Yr. CAGR % | 25.68 | 21.06 | 15.15 | 9.88 | 9.15 | |||||
Cash From Operations, 3 Yr. CAGR % | 10.45 | 15 | -30.79 | 30.59 | 20.72 | |||||
Capital Expenditures, 3 Yr. CAGR % | 13.38 | 46.53 | 52.53 | 38.85 | 5.76 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 5.72 | -37.92 | -39.14 | 23.61 | 56.5 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 5.72 | -37.87 | -39.18 | 23.64 | 56.41 | |||||
Dividend Per Share, 3 Yr. CAGR % | 42.34 | 7.92 | 0.04 | 6.26 | 7.72 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 24.38 | 18.48 | 8.99 | 5.55 | 3.74 | |||||
Gross Profit, 5 Yr. CAGR % | 25.14 | 18.05 | 8.2 | 5.01 | 3.42 | |||||
EBITDA, 5 Yr. CAGR % | 20.59 | 6.63 | -1.85 | 1.7 | 3.29 | |||||
EBITA, 5 Yr. CAGR % | 21.04 | 5.85 | -3.3 | 0.66 | 3.49 | |||||
EBIT, 5 Yr. CAGR % | 21.05 | 5.84 | -3.35 | 0.57 | 3.31 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 23.19 | 11.23 | 2.99 | 1.04 | 3.54 | |||||
Net Income, 5 Yr. CAGR % | 23.85 | 11.84 | 3.96 | 1.14 | 3.53 | |||||
Normalized Net Income, 5 Yr. CAGR % | 22.39 | 8.32 | 2.63 | 1.13 | 3.78 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 23.71 | 11.7 | 3.91 | 1.25 | 3.71 | |||||
Accounts Receivable, 5 Yr. CAGR % | 20.06 | 14.83 | 14.83 | 6.72 | 2.53 | |||||
Inventory, 5 Yr. CAGR % | 27.73 | 30.43 | 25.42 | 17.56 | 8.51 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 20.97 | 20.46 | 16.74 | 12.46 | 11.2 | |||||
Total Assets, 5 Yr. CAGR % | 24.75 | 22.34 | 18.61 | 14.38 | 12.72 | |||||
Tangible Book Value, 5 Yr. CAGR % | 25.38 | 23.35 | 19.85 | 15.26 | 12.66 | |||||
Common Equity, 5 Yr. CAGR % | 25.16 | 23.09 | 19.74 | 15.45 | 12.94 | |||||
Cash From Operations, 5 Yr. CAGR % | 8.55 | 10.23 | -13.06 | 22.47 | 14.23 | |||||
Capital Expenditures, 5 Yr. CAGR % | 7.06 | 8.42 | 39.26 | 22.9 | 28.53 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 18.99 | 18.35 | -1.38 | -2.01 | -13.52 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 18.99 | 18.41 | -1.42 | -1.99 | -13.51 | |||||
Dividend Per Share, 5 Yr. CAGR % | 40.09 | 26.14 | 22.59 | 9.46 | 4.59 |
Select your edition
All financial news and data tailored to specific country editions
















